IDEXX LABORATORIES, INC. 
By WESTBROOK, Maine, July 20, 2012 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), today reported that revenues for the second quarter of 2012 increased 6% to $335.6 million, from $317.9 million for the second quarter of 2011. Organic revenue growth[1] was 7%. Earnings per diluted share ("EPS") for the quarter ended June 30, 2012 increased 10% to $0.91, compared to $0.83 for the same period in the prior year.
(Logo: http://photos.prnewswire.com/prnh/20110602/NE13041LOGO )
"I am pleased with our second quarter results," stated Jonathan Ayers, Chairman and Chief Executive Officer. "With the first half of the year complete, we remain on track for 8-9% organic revenue growth for full year 2012, based on our continued strategy of innovation that supports our customers' growth and success around the globe."
"In the third quarter, we are introducing two new software offerings that advance our strategy of supporting the veterinarian in communicating the value of pet health to pet owners. The first, Pet Health Network® Pro, is a new client communication and education service for veterinarians, practice managers and their teams that offers an automated set of tools to strengthen the client relationship before, during and after each patient visit. The second, VetConnect® PLUS, is an innovative cloud-based tool that enables veterinarians to see all of a patient's diagnostic history generated from IDEXX in-house analyzers and IDEXX Reference Laboratories on one interactive screen, and share those results with pet owners in a client-friendly way. With easy access to a patient's blood work history, the veterinarian is able to more easily discern important trends and thus make better medical recommendations, while conveying those recommendations to the pet owner in a way that results in higher client compliance and practice growth."
"I am also pleased to announce some organizational changes that will position us for continued growth. We have created a new structure consisting of three operating Executive Vice Presidents and a set of key functional staff that will report to the CEO. The three operating Executive Vice Presidents collectively will have responsibility for essentially all of the Company's global operations, each with direct oversight of a portfolio of lines of business and geographic regions."
"I am pleased that Johnny Powers and Michael Williams, executives with extensive track records of success at IDEXX, have been elevated to two of these Executive Vice President positions. I am also very pleased to announce the recruitment of Jay Mazelsky for the third Executive Vice President role. Jay comes from Philips Healthcare, where he was most recently Senior Vice President and General Manager of their global Computed Tomography, Nuclear Medicine and Radiation Therapy Planning businesses. Jay is a seasoned executive who has extensive experience with product and software innovation in the healthcare field, and will be a great addition to our IDEXX team."
"In connection with these changes we also have promoted Merilee Raines, our Chief Financial Officer, and Bill Brown, our Chief Scientific Officer, to Executive Vice President in recognition of their respective critical roles in the past and future success of IDEXX."
"I look forward to working closely with this executive team, as well as our broader leadership team, in the years ahead to promote continued growth and innovation at IDEXX."
Revenue Performance
Please refer to the table below entitled "Revenues and Revenue Growth Analysis by Product and Service Categories" in conjunction with the following discussion.
Companion Animal Group. Companion Animal Group ("CAG") revenues for the second quarter of 2012 were $278.3 million compared to $259.7 million for the second quarter of 2011. Organic revenue growth of 8% was due primarily to growth in our instrument and consumables business and in our reference laboratory diagnostic and consulting services business. The revenue increase in our instruments and consumables business was largely the result of higher sales volumes of our Catalyst Dx® and ProCyte Dx® instruments and related consumables. In our reference laboratory diagnostic and consulting services business, revenues increased due to higher sales volumes driven primarily by the acquisition of new customers due, in part, to geographic expansion. Revenue from acquisitions contributed 1% to revenue growth and changes in foreign currency exchange rates reduced revenue growth by 3%.
Water. Water revenues for the second quarter of 2012 were $22.0 million compared to $21.5 million for the second quarter of 2011. Organic revenue growth of 5% was due primarily to higher Colilert® product sales volumes driven by new account acquisitions. Changes in foreign currency exchange rates reduced revenue growth by 3%.
Livestock and Poultry Diagnostics. Livestock and Poultry Diagnostics ("LPD") revenues for the second quarter of 2012 were $23.1 million compared to $25.4 million for the second quarter of 2011. The 4% decline in organic revenue was due primarily to lower sales of Bovine Spongiform Encephalopathy ("BSE" or otherwise commonly referred to as mad cow disease) tests resulting from changes in European Union BSE testing requirements. Effective July 1, 2011, the age at which healthy cattle to be slaughtered are required to be tested for BSE in the European Union was increased from 48 to 72 months, which is reducing the population of cattle tested for this disease. Changes in foreign currency exchange rates reduced revenue growth by 5%.
Additional Operating Results for the Second Quarter
Gross profit for the second quarter of 2012 increased $10.7 million, or 6%, to $184.7 million from $174.0 million for the second quarter of 2011. As a percentage of total revenue, gross profit increased slightly to 55%. The increase in the gross profit percentage was due primarily to the favorable impact of currency as hedging gains more than offset the net unfavorable impact of changes in foreign currency exchange rates.
Selling, general and administrative ("SG&A") expense for the second quarter of 2012 was $88.8 million, or 26% of revenue, compared to $84.1 million, or 26% of revenue, for the second quarter of 2011. The increase in SG&A expense was due primarily to increased personnel-related costs, partly offset by the favorable impact of changes in foreign currency exchange rates. Research and development ("R&D") expense for the second quarter of 2012 was $20.0 million, or 6% of revenue, compared to $18.6 million, or 6% of revenue for the second quarter of 2011. The increase in R&D expense resulted primarily from increased personnel-related costs and higher external consulting and development costs.
Supplementary Analysis of Results
The accompanying financial tables provide more information concerning our revenue and other operating results for the three and six months ended June 30, 2012.
Outlook for 2012
The Company provides the following guidance for the full year of 2012. The guidance reflects an assumption that the value of the U.S. dollar relative to other currencies will remain at our current assumptions of the euro at $1.23, the British pound at $1.53 and the Canadian dollar at $0.97 for the balance of 2012. Based on these assumptions, a 1% strengthening of the U.S. dollar would decrease revenue by approximately $4.5 million and operating profit by approximately $0.8 million on an annual basis. Fluctuations in foreign currency exchange rates from current assumptions could have a significant positive or negative impact on our actual results of operations for 2012.
-- Revenues are expected to be $1.30 to $1.31 billion, which represents
reported growth of 7% to 8% and organic growth of 8% to 9%. Organic
revenue growth is unchanged from our previous guidance. The decrease in
expected reported revenue compared to our previous guidance is due
exclusively to unfavorable changes in foreign currency exchange rates,
reflecting a strengthening of the U.S. dollar relative to other
currencies since the date of our previous guidance.
-- EPS are expected to be $3.05 to $3.10, compared to our previous guidance
of $3.07 to $3.12. The change in EPS guidance is due exclusively to the
unfavorable impact of changes in foreign currency exchange rates since
the date of our previous guidance.
-- Free cash flow is expected to be 105% to 110% of net income.[2]
-- Capital expenditures are expected to be approximately $60 million.
Conference Call and Webcast Information
IDEXX Laboratories will be hosting a conference call today at 9:00 a.m. (eastern) to discuss its second quarter results and management's outlook. To participate in the conference call, dial 1-612-288-0337 or 1-800-230-1074 and reference confirmation code 254010. An audio replay will be available through July 27, 2012 by dialing 1-320-365-3844 and referencing replay code 254010.
The call will also be available via live or archived webcast on the IDEXX Laboratories' web site at http://www.idexx.com.
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 5,000 people and offers products to customers in over 100 countries.
Note Regarding Forward-Looking Statements
This press release contains statements about the Company's business prospects and estimates of the Company's financial results for future periods that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "may," "anticipates," "intends," "would," "will," "plans," "believes," "estimates," "should," and similar words and expressions. These statements are based on management's expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management's expectations. Factors that could cause or contribute to such differences include the following: the Company's ability to develop, manufacture, introduce and market new products and enhancements to existing products; the Company's ability to achieve cost improvements in its worldwide network of laboratories and in the manufacture of in-clinic instruments;the Company's ability to identify acquisition opportunities, complete acquisitions and integrate acquired businesses; disruptions, shortages or pricing changes that affect the Company's purchases of products and materials from third parties, including from sole source suppliers; the Company's ability to manufacture complex biologic products; the impact of a weak economy on demand for the Company's products and services; the effectiveness of the Company's sales and marketing activities; the effect of government regulation on the Company's business, including government decisions about whether and when to approve the Company's products and decisions regarding labeling, manufacturing and marketing products; the impact of the resolution of the U.S. Federal Trade Commission investigation into the Company's marketing and sales practices; the impact of a change in the status of one of the Company's distributors on its results of operations;the Company's ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; the impact of distributor purchasing decisions on sales of the Company's products that are sold through distribution; the impact of competition, technological change, veterinary hospital consolidation, and the prevalence of buying consortiums on the markets for the Company's products; changes or trends in veterinary medicine that affect the rate of use of the Company's products and services by veterinarians; the impact of the Company's inexperience and small scale in the human point-of-care market; the effects of operations outside the U.S., including from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; the effects of interruptions to the Company's operations due to natural disasters or system failures; the impact of any class action litigation due to stock price volatility; the effect on the Company's stock price if quarterly or annual operations results do not meet expectations of market analysts or investors in future periods; and potential exposures related to our worldwide provision for income taxes and the potential loss of tax incentives. A further description of these and other factors can be found in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2012, in the section captioned "Risk Factors."
[1] Organic revenue growth for the second quarter of 2012 excludes revenue from business acquisitions, which contributed 1% to revenue growth, and the impact of changes in foreign currency exchange rates, which reduced revenue growth by 3%.
[2] Free cash flow is a non-U.S. GAAP measure. We calculate free cash flow as cash generated from operations, excluding our royalty prepayment in the first quarter of 2012, and tax benefits attributable to share-based compensation arrangements, reduced by our investments in fixed assets. We feel free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in fixed assets that are required to operate the business. We believe this is a common financial measure useful to further evaluate the results of operations. Refer to our reconciliation below for our calculation of free cash flow. With respect to this particular forward-looking projection, the Company is unable to provide a quantitative reconciliation at this time as the inputs to the measurement are difficult to predict and estimate and are primarily dependent on future events.
IDEXX Laboratories, Inc. and Subsidiaries
Consolidated Statement of Operations
Amounts in thousands except per share data (Unaudited)
Three Months Ended Six Months Ended
------------------ ----------------
June 30, June 30, June 30, June 30,
2012 2011 2012 2011
---- ---- ---- ----
Revenue: Revenue $335,649 $317,862 $658,325 $610,534
Expenses and
Income: Cost of revenue 150,960 143,829 298,862 281,576
--------------- ------- ------- ------- -------
Gross profit 184,689 174,033 359,463 328,958
Sales and marketing 54,539 50,974 112,171 101,959
General and administrative 34,275 33,140 70,453 65,736
Research and development 20,058 18,621 40,615 36,433
------------------------ ------ ------ ------ ------
Income from operations 75,817 71,298 136,224 124,830
Interest expense, net 446 363 1,203 722
--------------------- --- --- ----- ---
Income before provision for income taxes 75,371 70,935 135,021 124,108
Provision for income taxes 24,051 22,281 42,967 38,848
-------------------------- ------ ------ ------ ------
Net Income: Net income 51,320 48,654 92,054 85,260
Less: Noncontrolling interest in subsidiary's
earnings (losses) 3 (3) (6) (9)
---------------- --- --- --- ---
Net income attributable to stockholders $51,317 $48,657 $92,060 $85,269
Earnings per share: Basic $0.93 $0.85 $1.67 $1.49
------------------------- ----- ----- ----- -----
Earnings per share: Diluted $0.91 $0.83 $1.63 $1.45
--------------------------- ----- ----- ----- -----
Shares outstanding: Basic 55,079 57,276 55,143 57,366
------------------------- ------ ------ ------ ------
Shares outstanding: Diluted 56,211 58,727 56,345 58,934
--------------------------- ------ ------ ------ ------
IDEXX Laboratories, Inc. and Subsidiaries
Selected Operating Information(Unaudited)
Three Months Ended Six Months Ended
------------------ ----------------
June 30, June 30, June 30, June 30,
2012 2011 2012 2011
---- ---- ---- ----
Operating Gross profit 55.0% 54.8% 54.6% 53.9%
Ratios (as a Sales, marketing, general and
percentage of administrative expense 26.5% 26.5% 27.7% 27.5%
revenue): Research and development expense 6.0% 5.9% 6.2% 6.0%
Income from operations (1) 22.6% 22.4% 20.7% 20.5%
------------------------- ---- ---- ---- ----
International International revenue (in thousands) $135,950 $137,585 $268,234 $260,155
-------- -------- -------- --------
Revenue: International revenue as percentage
of total revenue 40.5% 43.3% 40.7% 42.6%
---------------- ---- ---- ---- ----
(1) Amounts presented may not recalculate due to rounding.
IDEXX Laboratories, Inc. and Subsidiaries
Segment Information
Amounts in thousands (Unaudited)
Three Months Ended Three Months Ended
------------------ ------------------
June 30, Percent of June 30, Percent of
2012 Revenue 2011 Revenue
---- ------- ---- -------
Revenue: CAG $278,294 $259,734
Water 21,983 21,510
LPD 23,060 25,367
Other 12,312 11,251
Total $335,649 $317,862
----- -------- --------
Gross Profit: CAG $147,908 53.1% $138,332 53.3%
Water 14,794 67.3% 12,968 60.3%
LPD 15,671 68.0% 17,335 68.3%
Other 4,575 37.2% 4,742 42.2%
Unallocated Amounts 1,741 N/A 656 N/A
------------------- ----- --- --- ---
Total $184,689 55.0% $174,033 54.8%
----- -------- ---- -------- ----
Income from
Operations: CAG $59,768 21.5% $58,270 22.4%
Water 10,196 46.4% 8,401 39.1%
LPD 5,810 25.2% 7,176 28.3%
Other 250 2.0% 309 2.8%
Unallocated Amounts (207) N/A (2,858) N/A
------------------- ---- --- ------ ---
Total $75,817 22.6% $71,298 22.4%
----- ------- ---- ------- ----
Six Months Ended Six Months Ended
---------------- ----------------
June 30, Percent of June 30, Percent of
2012 Revenue 2011 Revenue
---- ------- ---- -------
Revenue: CAG $546,367 $500,323
Water 41,565 40,475
LPD 45,242 49,306
Other 25,151 20,430
Total $658,325 $610,534
----- -------- --------
Gross Profit: CAG $287,309 52.6% $261,683 52.3%
Water 27,761 66.8% 24,359 60.2%
LPD 30,853 68.2% 33,882 68.7%
Other 9,892 39.3% 8,484 41.5%
Unallocated Amounts 3,648 N/A 550 N/A
------------------- ----- --- --- ---
Total $359,463 54.6% $328,958 53.9%
----- -------- ---- -------- ----
Income from
Operations: CAG $106,686 19.5% $101,242 20.2%
Water 18,491 44.5% 15,348 37.9%
LPD 11,076 24.5% 14,326 29.1%
Other 788 3.1% (241) (1.2%)
Unallocated Amounts (817) N/A (5,845) N/A
------------------- ---- --- ------ ---
Total $136,224 20.7% $124,830 20.5%
----- -------- ---- -------- ----
IDEXX Laboratories, Inc. and Subsidiaries
Revenues and Revenue Growth Analysis by Product and Service Categories
Amounts in thousands (Unaudited)
Net Revenue Three Three Dollar Percentage PercentageChange fromCurrency
(1) Percentage Organic
Months Months Ended Change Change Change from Revenue
June 30, 2011 Growth(3)
Ended June Acquisitions (2)
30, 2012
--- --------
CAG $278,294 $259,734 $18,560 7.1% (2.5%) 1.4% 8.2%
Water 21,983 21,510 473 2.2% (2.5%) - 4.7%
LPD 23,060 25,367 (2,307) (9.1%) (5.3%) - (3.8%)
Other 12,312 11,251 1,061 9.4% (1.5%) - 10.9%
----- ------ ------ ----- --- ----- --- ----
Total $335,649 $317,862 $17,787 5.6% (2.6%) 1.1% 7.1%
----- -------- -------- ------- --- ----- --- ---
Net CAG Revenue Three Three Dollar Percentage Percentage Percentage Organic
Revenue
Growth(3)
Months Months Ended
June 30, 2011 Change Change Change from Change from
Ended June Currency (1) Acquisitions
(2)
30, 2012
--- --------
Instruments and consumables $104,243 $98,603 $5,640 5.7% (2.8%) - 8.5%
Rapid assay products 45,577 44,193 1,384 3.1% (1.1%) - 4.2%
Reference laboratory diagnostic and
consulting services 106,385 99,087 7,298 7.4% (3.0%) 3.6% 6.8%
Practice management and digital
imaging systems 22,089 17,851 4,238 23.7% (0.4%) - 24.1%
Net CAG revenue $278,294 $259,734 $18,560 7.1% (2.5%) 1.4% 8.2%
--------------- -------- -------- ------- --- ----- --- ---
(1) The percentage change from currency is a non-U.S. GAAP measure. It represents the percentage change in revenue resulting from the difference between the average exchange rates during the three months ended June 30, 2012 and the same period of the prior year applied to foreign currency denominated revenues for the three months ended June 30, 2012.
(2) The percentage change from acquisitions is a non-U.S. GAAP measure. It represents the percentage change in revenue during the three months ended June 30, 2012 compared to the three months ended June 30, 2011 attributed to acquisitions subsequent to March 31, 2011.
(3) Organic revenue growth is a non-U.S. GAAP measure and represents the percentage change in revenue during the three months ended June 30, 2012 compared to the three months ended June 30, 2011 net of acquisitions and the effect of changes in foreign currency exchange rates.
IDEXX Laboratories, Inc. and Subsidiaries
Revenues and Revenue Growth Analysis by Product and Service Categories
Amounts in thousands (Unaudited)
Net Revenue Six Months Six Months PercentageChange fromAcquisitions
Ended June 30, Ended June 30, (2)
2012 2011 Dollar Percentage Percentage Organic
Change Change Change from Revenue Growth(3)
Currency (1)
--- -----------
CAG $546,367 $500,323 $46,044 9.2% (1.5%) 1.4% 9.3%
Water 41,565 40,475 1,090 2.7% (1.5%) - 4.2%
LPD 45,242 49,306 (4,064) (8.2%) (3.5%) - (4.7%)
Other 25,151 20,430 4,721 23.1% (0.5%) - 23.6%
----- ------ ------ ----- ---- ----- --- ----
Total $658,325 $610,534 $47,791 7.8% (1.7%) 1.2% 8.3%
----- -------- -------- ------- --- ----- --- ---
Net CAG Revenue Six Months Six Months
Ended June 30, Ended June 30,
2012 2011 Dollar Percentage Percentage Percentage Organic
Change Change Change from Change from Revenue Growth(3)
Currency (1) Acquisitions
(2)
--- ----------- -------------
Instruments and consumables $206,240 $192,490 $13,750 7.1% (1.7%) - 8.8%
Rapid assay products 89,241 82,810 6,431 7.8% (0.6%) - 8.4%
Reference laboratory diagnostic and
consulting services 208,247 188,215 20,032 10.6% (1.9%) 3.8% 8.7%
Practice management and digital
imaging systems 42,639 36,808 5,831 15.8% (0.2%) - 16.0%
Net CAG revenue $546,367 $500,323 $46,044 9.2% (1.5%) 1.4% 9.3%
--------------- -------- -------- ------- --- ----- --- ---
(1) The percentage change from currency is a non-U.S. GAAP measure. It represents the percentage change in revenue resulting from the difference between the average exchange rates during the six months ended June 30, 2012 and the same period of the prior year applied to foreign currency denominated revenues for the six months ended June 30, 2012.
(2) The percentage change from acquisitions is a non-U.S. GAAP measure. It represents the percentage change in revenue during the six months ended June 30, 2012 compared to the six months ended June 30, 2011 attributed to acquisitions subsequent to December 31, 2010.
(3) Organic revenue growth is a non-U.S. GAAP measure and represents the percentage change in revenue during the six months ended June 30, 2012 compared to the six months ended June 30, 2011 net of acquisitions and the effect of changes in foreign currency exchange rates.
IDEXX Laboratories, Inc. and Subsidiaries
Consolidated Balance Sheet
Amounts in thousands (Unaudited)
June 30, December 31,
2012 2011
---- ----
Assets: Current Assets:
Cash and cash equivalents $201,813 $183,895
Accounts receivable, net 147,159 141,275
Inventories 143,703 133,099
Other current assets 62,632 65,958
-------------------- ------ ------
Total current assets 555,307 524,227
-------------------- ------- -------
Property and equipment, net 220,580 216,777
--------------------------- ------- -------
Other long-term assets, net 291,430 289,810
--------------------------- ------- -------
Total assets $1,067,317 $1,030,814
------------ ---------- ----------
Liabilities
and
Stockholders'
Equity: Current Liabilities:
Accounts payable $29,706 $36,551
Accrued liabilities 128,478 141,383
Debt 244,945 243,917
Deferred revenue 16,022 15,028
---------------- ------ ------
Total current liabilities 419,151 436,879
------------------------- ------- -------
Long-term debt, net of current portion 2,021 2,501
Other long-term liabilities 56,204 51,841
--------------------------- ------ ------
Total long-term liabilities 58,225 54,342
--------------------------- ------ ------
Total stockholders' equity 589,933 539,579
Noncontrolling interest 8 14
----------------------- --- ---
Total equity 589,941 539,593
------------ ------- -------
Total liabilities and stockholders'
equity $1,067,317 $1,030,814
------------------------------------ ---------- ----------
IDEXX Laboratories, Inc. and Subsidiaries
Selected Balance Sheet Information(Unaudited)
June 30, March 31, December 31, September 30, June 30,
2012 2012 2011 2011 2011
---- ---- ---- ---- ----
Selected
Balance Sheet Days sales outstanding (1) 41.9 42.7 41.0 43.1 41.2
Information: Inventory turns (2) 1.8 1.8 1.8 1.7 1.7
(1) Days sales outstanding represents the average of the accounts receivable balances at the beginning and end of each quarter divided by revenue
for that quarter, the result of which is then multiplied by 91.25 days.
(2) Inventory turns represents inventory-related cost of product sales for the 12 months preceding each quarter-end divided by the inventory balance
at the end of the quarter.
IDEXX Laboratories, Inc. and Subsidiaries
Consolidated Statement of Cash Flows
Amounts in thousands (Unaudited)
Six Months Ended
----------------
June 30, June 30,
2012 2011
---- ----
Operating: Cash Flows from Operating Activities:
Net income $92,054 $85,260
Non-cash charges 32,458 34,316
Changes in assets and liabilities (39,766) (20,412)
Tax benefit from share-based compensation arrangements (5,946) (10,854)
------------------------------------------------------
Net cash provided by operating activities 78,800 88,310
----------------------------------------- ------ ------
Investing: Cash Flows from Investing Activities:
Purchases of property and equipment (24,301) (26,173)
Proceeds from disposition of pharmaceutical product lines 3,000 3,000
Proceeds from sale of property and equipment 45 218
Acquisition of intangible asset (900) -
Net cash used by investing activities (22,156) (22,955)
------------------------------------- ------- -------
Financing: Cash Flows from Financing Activities:
Borrowings on revolving credit facilities, net 1,000 3,486
Payment of notes payable (452) (425)
Repurchases of common stock (55,006) (98,419)
Proceeds from the exercise of stock options and employee stock purchase plans 10,247 19,367
Tax benefit from share-based compensation arrangements 5,946 10,854
---
Net cash used by financing activities (38,265) (65,137)
------------------------------------- ------- -------
Net effect of changes in exchange rates on cash (461) 2,265
----------------------------------------------- ---- -----
Net increase in cash and cash equivalents 17,918 2,483
----------------------------------------- ------ -----
Cash and cash equivalents, beginning of period 183,895 156,915
---------------------------------------------- ------- -------
Cash and cash equivalents, end of period $201,813 $159,398
---------------------------------------- -------- --------
IDEXX Laboratories, Inc. and Subsidiaries
Free Cash Flow
Amounts in thousands (Unaudited)
Six Months Ended
----------------
June 30, June 30,
2012 2011
---- ----
Free Cash
Flow: Net cash provided by operating activities 78,800 88,310
Royalty prepayment to obtain exclusive patent rights 6,250 -
Financing cash flows attributable to tax benefits from share-based
compensation arrangements 5,946 10,854
Purchases of property and equipment (24,301) (26,173)
----------------------------------- ------- -------
Free cash flow 66,695 72,991
-------------- ------ ------
IDEXX Laboratories, Inc. and Subsidiaries
Common Stock Repurchases
Amounts in thousands except per share data (Unaudited)
Three Months Ended Six Months Ended
------------------ ----------------
June 30, June 30, June 30, June 30,
2012 2011 2012 2011
---- ---- ---- ----
Share repurchases during the period 319 759 652 1,297
Average price paid per share $85.84 $77.08 $84.32 $75.89
Shares remaining under repurchase authorization as of June 30, 2012 totaled 3,735,326.
Share repurchases do not include shares surrendered by employees in payment for the minimum
required
withholding taxes due on the vesting of restricted stock units and the settlement of deferred
stock units.
Contact: Merilee Raines, Chief Financial Officer, 1-207-556-8155
SOURCE IDEXX Laboratories, Inc.
